Vincristine

Microtubule inhibitor

MECHANISM OF ACTION

Disrupts M and S phase of mitosis

MECHANISM OF KIDNEY INJURY

CLINICAL KIDNEY SYNDROME

extra-renal; neutropenia, neuropathy, alopecia, hypersensitivity

CARDIOVASCULAR ADVERSE EFFECTS

LYTE ABNORMALITIES

RISK FACTORS

MITIGATION STRATEGIES

SUGGESTIONS

eGFR < 60 ml/min, no adjustment is needed

NOTES/COMMENTS

PHARMACOKINETICS

Molecular Weight

Volume of Distribution

Plasma Protein Binding

Metabolism

Bioavailability

Half-life elimination

85 hours

Time to peak

Excretion

80% feces, urine 10-20%

Dialyzable?

Non dialyzable

REF:

PATHOLOGY SLIDES:

ENTRY UPDATES:

Raad Chowdhury

United States

Sep 25, 2022

PARTNERS WITH